secwatch.observer — SEC 8-K summary
======================================

Issuer:     Onconetix, Inc. (ONCO)
CIK:        0001782107
Form:       8-K
Filed at:   2023-10-03T23:59:59+00:00
Accession:  0001013762-23-000742
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Blue Water Biotech issues Series A convertible to Veru to satisfy $4M payment
-----------------------------------------------------------------------------

- Entered exclusive 3-year distribution deal with Cardinal Health; start-up fee $15,500, monthly fee $7,000.
- Amended Veru asset purchase: $4M Sep 30 installment satisfied by $1M cash + 3,000 Series A Preferred shares.
- Series A Preferred converts to ~5.7M common shares at $0.5254, one-year lock, subject to shareholder approval by Dec 31, 2023.
- Preferred shares unregistered, liquidation preference $1,000/share, no voting except on significant matters.
- Company must use best efforts to obtain shareholder approval and include underlying shares in next resale registration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782107/000101376223000742/0001013762-23-000742-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782107/000101376223000742/ea186204-8k_bluewater.htm
  HTML page:      https://secwatch.observer/filing/0001013762-23-000742

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer